Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab zuvotolimod - ARS Pharmaceuticals

Next Previous
Drug Profile

Pertuzumab zuvotolimod - ARS Pharmaceuticals

Alternative Names: SBT-6050

Latest Information Update: 14 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silverback Therapeutics
  • Developer ARS Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Nov 2022 Silverback Therapeutics has been acquired and merged into ARS Pharmaceuticals
  • 07 Jul 2022 Silverback Therapeutics terminates a phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) due to strategic re-alignment(NCT05091528)
  • 07 Jul 2022 Silverback Therapeutics terminates a phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) due to strategic re-alignment(NCT05091528)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top